Building on bispecific antibodies, four of which have been approved by the FDA to treat relapsed/refractory multiple myeloma, ...

FDA granted Orphan Drug Designation to Sanofi’s SAR446523, a monoclonal antibody targeting GPRC5D, for relapsed/refractory ...

Sanofi's SAR446523 gains FDA orphan drug status, offering hope for relapsed multiple myeloma patients with its targeted ...

SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for ...

US FDA grants orphan drug designation to Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns to treat multiple myeloma: Paris Friday, August 1, 2025, 09:00 Hrs [IST] The US ...

On July 25, Leads Biolabs made its official debut on the Hong Kong Stock Exchange. Its shares surged as much as 117% intraday ...

Hospitals paradoxically house fast food outlets, raising health concerns. A U.S. poll shows most oppose such sales; India too ...

Panelists discuss that shifting talquetamab dosing from weekly to every 2 weeks improves response durability and patient ...